Barclays
VIVO

Barclays’s Meridian Bioscience Inc VIVO Stock Holding History

Barclays’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-200
Closed -$4K – 7420
2019
Q1 		$4K Sell
200
-300
-60% -$4.99K ﹤0.01% 6772
2018
Q4 		$9K Buy
500
+200
+67% +$3.41K ﹤0.01% 6235
2018
Q3 		$4K Sell
300
-11,400
-97% -$177K ﹤0.01% 6851
2018
Q2 		$186K Sell
11,700
-4,100
-26% -$61.2K ﹤0.01% 4781
2018
Q1 		$224K Buy
15,800
+10,200
+182% +$151K ﹤0.01% 4743
2017
Q4 		$78K Buy
5,600
+4,800
+600% +$70.3K ﹤0.01% 5434
2017
Q3 		$11K Sell
800
-5,500
-87% -$78.6K ﹤0.01% 6099
2017
Q2 		$99K Buy
6,300
+5,900
+1,475% +$85K ﹤0.01% 4921
2017
Q1 		$6K Sell
400
-8,800
-96% -$123K ﹤0.01% 6247
2016
Q4 		$163K Buy
9,200
+9,100
+9,100% +$160K ﹤0.01% 4385
2016
Q3 		$2K Sell
100
-1,000
-91% -$19.6K ﹤0.01% 6295
2016
Q2 		$21K Sell
1,100
-2,600
-70% -$51K ﹤0.01% 5256
2016
Q1 		$74K Buy
3,700
+1,100
+42% +$21.7K ﹤0.01% 4553
2015
Q4 		$52K Buy
2,600
+500
+24% +$9.59K ﹤0.01% 4771
2015
Q3 		$36K Sell
2,100
-2,400
-53% -$43.9K ﹤0.01% 5190
2015
Q2 		$81K Sell
4,500
-500
-10% -$9.27K ﹤0.01% 4826
2015
Q1 		$95K Buy
5,000
+4,900
+4,900% +$90.6K ﹤0.01% 4886
2014
Q4 		$2K Sell
100
-2,700
-96% -$46.3K ﹤0.01% 7138
2014
Q3 		$48K Buy
2,800
+100
+4% +$1.97K ﹤0.01% 5918
2014
Q2 		$54K Sell
2,700
-400
-13% -$8.22K ﹤0.01% 5883
2014
Q1 		$65K Buy
3,100
+2,400
+343% +$55K ﹤0.01% 5787
2013
Q4 		$18K Sell
700
-400
-36% -$9.83K ﹤0.01% 6773
2013
Q3 		$25K Sell
1,100
-700
-39% -$16.3K ﹤0.01% 6433
2013
Q2 		$39K Buy
+1,800
New +$38.8K ﹤0.01% 6480

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's VIVO Position: Q1 2023 in Review

Barclays sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,293 shares — an estimated $1.67M sold.

Barclays first reported a position in VIVO in Q2 2013 and held it in 37 quarters. The position peaked at $1.67M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Barclays reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 50,293 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.67M.
  • Barclays first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 37 quarters.
  • Barclays's Meridian Bioscience Inc position peaked at $1.67M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.